Etoricoxib

Catalog No.S4651 Synonyms: Arcoxia, MK-663, MK-0663, Tauxib, Algix, Nucoxia

For research use only.

Etoricoxib (Arcoxia, MK-663, MK-0663, Tauxib, Algix, Nucoxia) is a new COX-2 selective inhibitor with anti-inflammatory, antipyretic, analgesic, and potential antineoplastic properties.

Etoricoxib Chemical Structure

CAS No. 202409-33-4

Selleck's Etoricoxib has been cited by 1 Publication

Purity & Quality Control

Choose Selective COX Inhibitors

Other COX Products

Biological Activity

Description Etoricoxib (Arcoxia, MK-663, MK-0663, Tauxib, Algix, Nucoxia) is a new COX-2 selective inhibitor with anti-inflammatory, antipyretic, analgesic, and potential antineoplastic properties.
Targets
COX-2 [1]
In vivo The preferential cyclooxygenase-2 inhibitor etoricoxib significantly reduces the anticonvulsant action of phenytoin and significantly increases the beneficial action of diazepam against maximal electroshock and pentylenetetrazole-induced convulsions in a mouse model[1]. Etoricoxib has the potential to act as an anti-apoptotic and anti- proliferative agent in the colon[2].

Protocol (from reference)

Cell Research:

[3]

  • Cell lines: Human colon carcinoma cell line HCT-116
  • Concentrations: 200 μM
  • Incubation Time: 2 h
  • Method:

    Human colon carcinoma cell line HCT-116 are treated with various coxibs for 2 h. Subsequently, the cells are harvested and the sphingolipids isolated and determined by LC-MS/MS.

Animal Research:

[1]

  • Animal Models: Adult albino male mice
  • Dosages: 10 mg/kg
  • Administration: p.o.

Solubility (25°C)

In vitro

DMSO 71 mg/mL
(197.85 mM)
Water Insoluble
Ethanol '46 mg/mL

Chemical Information

Molecular Weight 358.84
Formula

C18H15ClN2O2S

CAS No. 202409-33-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05142098 Not yet recruiting Drug: Dexamethasone|Drug: Etoricoxib 60 mg Effect of Drug Dow University of Health Sciences January 1 2022 Early Phase 1
NCT02503839 Unknown status Drug: etoricoxib|Biological: H56:IC31 Tuberculosis Anne Margarita Dyrhol Riise|University of Oslo|Statens Serum Institut|Haukeland University Hospital|Oslo University Hospital November 2015 Phase 1
NCT02568735 Completed Drug: Dexketoprofen|Drug: Etoricoxib Pain Postoperative Kuopio University Hospital January 2013 Phase 4
NCT01572675 Completed Drug: etorocoxib|Drug: celecoxib Osteoarthritis Merck Sharp & Dohme Corp. June 2012 --
NCT01264237 Unknown status Drug: Etoricoxib|Drug: Placebo Postherpetic Neuralgia|Neuralgia Analgesic Solutions|Merck Sharp & Dohme Corp. March 2011 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Etoricoxib | Etoricoxib supplier | purchase Etoricoxib | Etoricoxib cost | Etoricoxib manufacturer | order Etoricoxib | Etoricoxib distributor